News

August 05, 2009
ImmunoGen, Inc. Announces Webcast of Presentation at the 29th Annual Canaccord Adams Global Growth Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 5, 2009-- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the 29th Annual Canaccord Adams Global Growth Conference will be webcast live. The presentation is scheduled to begin at 1:30 p.m. ET on August 12, 2009, and will be given at the Intercontinental Hotel in Boston. The presentation will provide an update on ImmunoGen.

The webcast can be accessed through the Investor Information section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until August 19, 2009.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and linkage of potent cancer-cell killing agents (CKAs) to such antibodies. The Company’s proprietary Targeted Antibody Payload (TAP) technology consists of ImmunoGen’s highly potent CKAs, which have been designed specifically for delivery by antibodies to cancer cells, and the Company’s engineered linkers, which direct the activation of the CKA inside a cancer cell. Compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s own programs and its collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, T-DM1, is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.

Source: ImmunoGen, Inc.

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?